Sensei Biotherapeutics (NASDAQ:SNSE) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a research report sent to investors on Friday,Benzinga reports. They currently have a $4.00 target price on the stock.

Sensei Biotherapeutics Price Performance

SNSE stock opened at $0.51 on Friday. The business’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.49. The firm has a market capitalization of $12.78 million, a P/E ratio of -0.43 and a beta of 0.16. Sensei Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, March 28th. The company reported ($0.27) earnings per share for the quarter, meeting the consensus estimate of ($0.27). On average, analysts expect that Sensei Biotherapeutics will post -1.17 EPS for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI grew its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.